An LED-based intraoral device for photobiomodulation therapy was safe and reduced severe oral mucositis in patients with head ...
The REMS program for vandetanib in the treatment of patients with medullary thyroid cancer has been removed by the FDA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback